Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247):: Relation to species differences in hepatotoxicity

被引:9
作者
Kenny, JR
Maggs, JL
Tettey, JNA
Harrell, AW
Parker, SG
Clarke, SE
Park, BK
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
[2] GlaxoSmithKline, Preclin Dev, Welwyn Garden City, Herts, England
关键词
D O I
10.1124/dmd.104.001677
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
SB-209247 [(E)-3-[6-[[(2,6-dichlorophenyl)-thio] methyl]-3-(2-phenylethoxy)2- pyridinyl]-2-propenoic acid], an anti-inflammatory leukotriene B-4 receptor antagonist, was associated in beagle dogs but not male rats with an inflammatory hepatopathy. It also produced a concentration-dependent ( 10 - 1000 muM) but equal leakage of enzymes from dog and rat precision-cut liver slices. The hepatic metabolism of SB-209247 was investigated with reference to the formation of reactive acyl glucuronides. [C-14] SB-209247 (100 mumol/ kg) administered i.v. to anesthetized male rats was eliminated by biliary excretion of the acyl glucuronides of the drug and its sulfoxide. After 5 h, 1.03 +/- 0.14% ( mean +/- S. E. M., n = 4) of the dose was bound irreversibly to liver tissue. The sulfoxide glucuronide underwent pH-dependent rearrangement in bile more rapidly than did the SB-209247 conjugate. [C-14] SB-209247 was metabolized by sulfoxidation and glucuronidation in rat and dog hepatocytes, and approximately 1 to 2% of [C-14] SB-209247 (100 muM) became irreversibly bound to cellular material. [C-14] SB-209247 sulfoxide and glucuronide were the only metabolites produced by dog, rat, and human liver microsomes in the presence of NADPH and UDP-glucuronic acid (UDPGA), respectively. V-max values for [C-14] SB-209247 glucuronidation by dog, rat, and human microsomes were 2.6 +/- 0.1, 1.2 +/- 0.1, and 0.4 +/- 0.0 nmol/min/mg protein, respectively. Hepatic microsomes from all three species catalyzed UD-PGA-dependent but not NADPH-dependent irreversible binding of [C-14] SB-209247 (100 - 250 muM) to microsomal protein. Although a reactive acyl glucuronide was formed by microsomes from every species, the binding did not differ between species. Therefore, neither the acute cellular injury nor glucuronidation-driven irreversible protein binding in vitro is predictive of the drug-induced hepatopathy.
引用
收藏
页码:271 / 281
页数:11
相关论文
共 40 条
[31]   Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: A novel role for Phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones? [J].
Sallustio, BC ;
Harkin, LA ;
Mann, MC ;
Krivickas, SJ ;
Burcham, PC .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 147 (02) :459-464
[32]  
Sallustio BC, 2001, DRUG METAB DISPOS, V29, P1535
[33]   REACTIVITY OF CYSTEINE S-CONJUGATE SULFOXIDES - FORMATION OF S-[1-CHLORO-2-(S-GLUTATHIONYL)VINYL]-L-CYSTEINE SULFOXIDE BY THE REACTION OF S-(1,2-DICHLOROVINYL)-L-CYSTEINE SULFOXIDE WITH GLUTATHIONE [J].
SAUSEN, PJ ;
ELFARRA, AA .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (06) :655-660
[34]   Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats [J].
Seitz, S ;
Boelsterli, UA .
GASTROENTEROLOGY, 1998, 115 (06) :1476-1482
[35]   Role of neutrophils in hepatotoxicity induced by oral acetaminophen administration in rats [J].
Smith, GS ;
Nadig, DE ;
Kokoska, ER ;
Solomon, H ;
Tiniakos, DG ;
Miller, TA .
JOURNAL OF SURGICAL RESEARCH, 1998, 80 (02) :252-258
[36]  
Soars MG, 2001, DRUG METAB DISPOS, V29, P121
[37]  
STROM SC, 1982, J NATL CANCER I, V68, P771
[38]   Intracellular localization and metabolism of the phenanthridinium trypanocide, ethidium bromide, by isolated rat hepatocytes [J].
Tettey, JNA ;
Skellern, GG ;
Midgley, JM ;
Grant, MH ;
Wilkinson, R ;
Pitt, AR .
XENOBIOTICA, 1999, 29 (04) :349-360
[39]  
Ward KW, 1999, DRUG METAB DISPOS, V27, P1232
[40]   Induction of cytokine release by the acyl glucuronide of mycophenolic acid:: A link to side effects? [J].
Wieland, E ;
Shipkova, M ;
Schellhaas, U ;
Schütz, E ;
Niedmann, PD ;
Armstrong, VW ;
Oellerich, M .
CLINICAL BIOCHEMISTRY, 2000, 33 (02) :107-113